Similar Papers

Paper Title
Journal
Date
Author
The Efficacy and Safety of Pembrolizumab in Advanced Melanoma: A Meta-Analysis Study
Abdulaziz Khalid Albarti ... Saleh Turki Hamad Alothman
EVOLUTIONARY STUDIES IN IMAGINATIVE CULTURE | VOL. -
Abdulaziz Khalid Albarti, et. al. Abdulaziz Khalid Albarti ... Saleh Turki Hamad Alothman
27 Oct 2024
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
Abdulaali R Almutairi ... Brian L Erstad
Frontiers in Oncology | VOL. 10
Abdulaali R Almutairi, et. al.Abdulaali R Almutairi ... Brian L Erstad
11 Feb 2020
Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review.
Giulio Rizzetto ... Elisa Molinelli
International Journal of Molecular Sciences | VOL. 24
Giulio Rizzetto, et. al.Giulio Rizzetto ... Elisa Molinelli
03 Aug 2023
Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma
Jennifer E Yeh ... Jennifer Y Lin
JAAD Case Reports | VOL. 27
Jennifer E Yeh, et. al.Jennifer E Yeh ... Jennifer Y Lin
22 Jul 2022
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Marcela Carausu ... Michail Ignatiadis
Annals of Oncology | VOL. 36
Marcela Carausu, et. al.Marcela Carausu ... Michail Ignatiadis
01 Feb 2025
FOxTROT: is anti-EGFR a good dancing partner?
Clara Montagut ... Joana Vidal
Annals of Oncology | VOL. -
Clara Montagut, et. al.Clara Montagut ... Joana Vidal
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.